Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies.
Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab JP01 andJP02 Study Group. Kabashima K, et al. Among authors: matsumura t. Br J Dermatol. 2022 Apr;186(4):642-651. doi: 10.1111/bjd.20873. Epub 2021 Dec 21. Br J Dermatol. 2022. PMID: 34726262 Free PMC article. Clinical Trial.
Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial.
Kabashima K, Matsumura T, Hayakawa Y, Kawashima M; Nemolizumab-JP01 Study Group. Kabashima K, et al. Among authors: matsumura t. J Dermatolog Treat. 2023 Dec;34(1):2177096. doi: 10.1080/09546634.2023.2177096. J Dermatolog Treat. 2023. PMID: 36779675 Free article. Clinical Trial.
Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A, Katsunuma T, Matsumura T, Komazaki H; Nemolizumab-JP04 Study Group. Igarashi A, et al. Among authors: matsumura t. Br J Dermatol. 2023 Dec 20;190(1):20-28. doi: 10.1093/bjd/ljad268. Br J Dermatol. 2023. PMID: 37522351 Clinical Trial.
Diffuse cutaneous mastocytosis responding to cyproheptadine.
Enomoto U, Kusakabe H, Matsumura T, Kuno T, Tamai H, Kiyokane K. Enomoto U, et al. Among authors: matsumura t. Clin Exp Dermatol. 1999 Jan;24(1):16-8. doi: 10.1046/j.1365-2230.1999.00397.x. Clin Exp Dermatol. 1999. PMID: 10233642
Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma.
Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, Ozasa K, Watanabe Y, Hayashi K, Maeda K, Kinoshita S, Matsumura T, Ohnishi Y, Hotta Y, Takahashi R, Kato MV, Ishizaki K, Sasaki MS, Horsthemke B, Minoda K, Sakai T. Ohtani-Fujita N, et al. Among authors: matsumura s, matsumura t. Cancer Genet Cytogenet. 1997 Oct 1;98(1):43-9. doi: 10.1016/s0165-4608(96)00395-0. Cancer Genet Cytogenet. 1997. PMID: 9309117
A prediction model of abnormal acid reflux in gastroesophageal reflux disease.
Sonoda M, Matsumura T, Dao HV, Shiko Y, Do PN, Nguyen BP, Okimoto K, Akizue N, Ohyama Y, Mamiya Y, Nakazawa H, Takahashi S, Horio R, Goto C, Kurosugi A, Kaneko T, Ohta Y, Saito K, Taida T, Kikuchi A, Fujie M, Kato J, Dao LV, Kato N. Sonoda M, et al. Among authors: matsumura t. J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16602. Online ahead of print. J Gastroenterol Hepatol. 2024. PMID: 38747056
2,157 results